Pilot Study of Combination 5-Fluorouracil, Cisdiamminedichloroplatinum II, and Radiation Therapy for Grade III and IV Astrocytomas

Publisher Website
Google Scholar
Abstract
NIneteen patients with biopsy-proven high-grade astrocytomas recieved as initial treatment whole-brain radiation and combination chemotherapy with 5-fluorouracil (5-FU), 1,000 mg/m2/24 h as a continuous infusion for 96 h, and bolus cisdiamminedichloroplatinum II (CDDP), 100 mg/m2. Chemotherapy cycles were repeated on day 21, then every 28 days until progression or completion of six cycles. All 19 patients completed one cycle of chemotherapy. Toxicity was moderate, with cytopenias, nausea, vomiting, diarrhea, stomatitis, and reversible azotemia. Survival ranged from 2 to 160 + weeks, with a median of 35 weeks. The survival of the pilot group was compared with historical controls treated with radiation plus 1,3-bis(2-chloroethyl)-1 nitrosourea (BCNU). Controls were similar in histology, age, performance score, and survival, without statistically significant differences. The combination of radiation therapy, continuous-infusion 5-FU, and bolus CDDP as described here for high-grade astrocytomas is moderately toxic and appears to offer no survival advantage compared with radiation therapy plus BCNU.

This publication has 0 references indexed in Scilit: